Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1174)	6/11/1998 3:18:00 PM
From: Steve Harmon	Respond to of 2742

Somebody is continuing to play with Cistron's stock. With $13 million in cash and a tiny burn rate, Cistron's mgt. has full control of its own stock price. Why is this being allowed to happen? Bluestone looks like they will get a REAL low price on the other 400,000 warrants! Good going Bluestone>>>You really are Nasdaq experts!(Good hypothesis John de Castro post #1167)

To: Steve Harmon who wrote (1174)	6/11/1998 9:43:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

The Immune Response/Agouron partnership announcement was an eye-catcher this afternoon. CIST technology should be of interest to IMNR for several of their programs. Hopefully Galton/BlueStone and IMNR have been in discussions. Rudy

To: Steve Harmon who wrote (1174)	6/18/1998 4:36:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

<<I am certain of the next two statements: 1)Smithkline has a interest in the results of Cistron's flu vaccine study with Novavax.>> Steve, Graphical results of the Cistron/Novavax study presented last Nov. are shown on CIST's website. It's sort of hidden, so I would guess not everyone has seen this. Go to cistronbio.com and scroll to the bottom of the page. Very impressive results. After the boost injection, anti-flu titer with Novasome/flu/IL-1b is roughly 10x higher than flu alone. I agree with you. Smithkline and other vaccine developers should be interested in this technology. So why hasn't this been partnered??? Rudy